Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Rebif er større end risiciene ved behandling af patienter med recidiverende dissemineret sklerose.
The Committee for Medicinal Products for Human Use (CHMP) decided that Rebif’ s benefits are greater than its risks for the treatment of relapsing MS.